Search research articles
Contact Us
Filters
Showing results (141-150 of 152) with videos related to
Page
of 16
Sort By:
BMC Medical Informatics and Decision Making
|
May 13, 2021
Head to head randomized trial of two decision aids for prostate cancer
Angela Fagerlin, Margaret Holmes-Rovner, Timothy P Hofer, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
February 1, 2024
Development of Patient Safety Measures to Identify Inappropriate Diagnosis of Common Infections
Andrea T White, Valerie M Vaughn, Lindsay A Petty, et al.
Health Affairs (Project Hope)
|
July 5, 2023
Adopting Weight-Based Dosing With Pharmacy-Level Stewardship Strategies Could Reduce Cancer Drug Spending By Millions
Alex K Bryant, Zoey Chopra, Donna M Edwards, et al.
JAMA Internal Medicine
|
September 14, 2020
Identifying Recommendations for Stopping or Scaling Back Unnecessary Routine Services in Primary Care
Eve A Kerr, Mandi L Klamerus, Adam A Markovitz, et al.
JAMA Internal Medicine
|
March 25, 2024
Inappropriate Diagnosis of Pneumonia Among Hospitalized Adults
Ashwin B Gupta, Scott A Flanders, Lindsay A Petty, et al.
JCO Precision Oncology
|
June 3, 2026
Communication With Clinicians and Relatives About Cascade Genetic Testing in Cancer Patients With Germline Pathogenic Variants
Allison W Kurian, Paul Abrahamse, Allison Furgal, et al.
JCO Oncology Practice
|
June 18, 2026
Maintenance Pemetrexed/Pembrolizumab Versus Pembrolizumab in Non-Small Cell Lung Cancer: A Propensity Score-Weighted Analysis
Garth W Strohbehn, Molly C Tokaz, Daniel Sanghoon Shin, et al.
JAMA Network Open
|
January 15, 2021
A Method to Quantify Mean Hypertension Treatment Daily Dose Intensity Using Health Care System Data
Lillian Min, Jin-Kyung Ha, Carole E Aubert, et al.
JAMA
|
June 5, 2023
Germline Genetic Testing After Cancer Diagnosis
Allison W Kurian, Paul Abrahamse, Allison Furgal, et al.
The Lancet. Oncology
|
May 31, 2024
Projected environmental and public health benefits of extended-interval dosing: an analysis of pembrolizumab use in a US national health system
Alex K Bryant, Jacqueline R Lewy, R Daniel Bressler, et al.
Page
of 16
Search research articles
Search
Showing results (141-150 of 152) with videos related to
Sort By:
Page
of 16
BMC Medical Informatics and Decision Making
|
May 13, 2021
Head to head randomized trial of two decision aids for prostate cancer
Angela Fagerlin, Margaret Holmes-Rovner, Timothy P Hofer, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
February 1, 2024
Development of Patient Safety Measures to Identify Inappropriate Diagnosis of Common Infections
Andrea T White, Valerie M Vaughn, Lindsay A Petty, et al.
Health Affairs (Project Hope)
|
July 5, 2023
Adopting Weight-Based Dosing With Pharmacy-Level Stewardship Strategies Could Reduce Cancer Drug Spending By Millions
Alex K Bryant, Zoey Chopra, Donna M Edwards, et al.
JAMA Internal Medicine
|
September 14, 2020
Identifying Recommendations for Stopping or Scaling Back Unnecessary Routine Services in Primary Care
Eve A Kerr, Mandi L Klamerus, Adam A Markovitz, et al.
JAMA Internal Medicine
|
March 25, 2024
Inappropriate Diagnosis of Pneumonia Among Hospitalized Adults
Ashwin B Gupta, Scott A Flanders, Lindsay A Petty, et al.
JCO Precision Oncology
|
June 3, 2026
Communication With Clinicians and Relatives About Cascade Genetic Testing in Cancer Patients With Germline Pathogenic Variants
Allison W Kurian, Paul Abrahamse, Allison Furgal, et al.
JCO Oncology Practice
|
June 18, 2026
Maintenance Pemetrexed/Pembrolizumab Versus Pembrolizumab in Non-Small Cell Lung Cancer: A Propensity Score-Weighted Analysis
Garth W Strohbehn, Molly C Tokaz, Daniel Sanghoon Shin, et al.
JAMA Network Open
|
January 15, 2021
A Method to Quantify Mean Hypertension Treatment Daily Dose Intensity Using Health Care System Data
Lillian Min, Jin-Kyung Ha, Carole E Aubert, et al.
JAMA
|
June 5, 2023
Germline Genetic Testing After Cancer Diagnosis
Allison W Kurian, Paul Abrahamse, Allison Furgal, et al.
The Lancet. Oncology
|
May 31, 2024
Projected environmental and public health benefits of extended-interval dosing: an analysis of pembrolizumab use in a US national health system
Alex K Bryant, Jacqueline R Lewy, R Daniel Bressler, et al.
Page
of 16